FINWIRES · TerminalLIVE
FINWIRES

Aurora Cannabis Urges Shareholders to Reject Curaleaf's Takeover Bid

By

Aurora Cannabis (ACB.TO) urged shareholders to reject Curaleaf Holdings (CURA.TO)'s unsolicited takeover bid, saying that the offer undervalues the company, Aurora said Wednesday.

Aurora said Curaleaf is seeking to acquire Aurora's assets at a discount, adding that Curaleaf's debt of over C$1 billion would put Aurora shareholders at risk.

The board of Aurora recommended that Aurora shareholders take no action on the bid, and told shareholders who have tendered their shares to the bid to withdraw those shares.

Aurora said the company's standalone strategy to exit lower-margin businesses, expand cultivation and manufacturing capacity, and develop an international platform offers better value for shareholders.

"Curaleaf has over a C$1 billion in debt and is asking shareholders to give up ownership of a stronger, debt-free and growing global medical cannabis company in exchange for an offer with intentionally limited upside, that does not reflect Aurora's fundamental value, exposes shareholders to Curaleaf's risks and would leave shareholders with limited voting influence in a combined company," Aurora Executive Chairman and CEO Miguel Martin said.

Related Articles

Mining & Metals

Alimentation Couche-Tard Q1 Adjusted EPS Rises to $0.90; Revenue Beats FactSet Estimate

Alimentation Couche-Tard (ATD.TO) said after the close Tuesday its fiscal first-quarter adjusted earnings per share rose to $0.90 from $0.78 in the prior-year period.Revenue for the period ended July 19 increased to $21.70 billion in the quarter ended July 19 from $17.35 billion a year earlier, exceeding the FactSet consensus estimate of $20.86 billion.The company also declared a quarterly dividend of C$0.22 per share for the first quarter of fiscal 2027, payable Sept. 25 to shareholders of record as of Sept. 11.Shares of the company closed up C$0.81 to C$84.28 on Toronto Stock Exchange.

$ATD.TO
Mining & Metals

Hammond Power Solutions Hikes Its Quarterly Dividend 5.5% to C$0.29 per Class B Share. The Higher Dividend Will Be Paid Sept. 24 to Shareholders of Record on Sept. 17

$HPS-A.TO
Mining & Metals

Cipher Pharmaceuticals' Ownership Of Certain Abscoria-Related Clinical Data Affirmed by US Court

Cipher Pharmaceuticals (CPH.TO) said Tuesday after trade that a New York federal court denied Sun Pharmaceuticals' petition to vacate an arbitrator's ruling concerning the ownership of certain clinical data.The court agreed with the arbitrator that Cipher owned clinical data that was used by Sun to launch a prescription anti-acne medication, Abscoria, in Canada in 2023.The arbitrator had awarded Cipher damages of C$4.2 million, a 15% royalty on net sales of Absorica in Canada from Jan. 1, 2026, and ending on Dec. 31, 2040. Also awarded was 80% of Cipher's out-of-pocket attorneys' fees and certain expenses related to the arbitration process, a statement said.The federal court awarded Cipher interest on the damages and its out-of-pocket attorneys' fees and certain expenses directly related to the arbitration process, at a rate of 9% per annum.Cipher Pharmaceuticals shares closed up C$0.51 at C$14.19 on the Toronto Stock Exchange.

$CPH.TO